Pharmacist-led education: a promising step towards optimal anticoagulation management in atrial fibrillation

This invited commentary refers to ‘Effects of intensive, targeted education by pharmacists on anticoagulant patients with atrial fibrillation: a multicentre randomized controlled trial from China’ by W. Xu et al. https://doi.org/10.1093/eurjcn/zvae092 The recent publication by Xu et al.,1 exploring the impact of pharmacist-led education on oral anticoagulation management in atrial fibrillation (AF) patients, offers valuable insights into optimizing healthcare delivery in China. This meticulously designed multicentre randomized controlled trial underscores the significant positive impact of structured patient education delivered by pharmacists. The study convincingly demonstrates that such interventions not only enhance disease-related knowledge and medication adherence but also contribute to a statistically significant reduction in bleeding events, a critical aspect of safe and effective anticoagulation therapy. The study’s findings carry particular weight considering the often-silent nature of atrial fibrillation. This frequently asymptomatic presentation poses a challenge to patient adherence to prescribed medication regimens, as individuals may not perceive the immediate need for consistent medication use. The study by Xu et al. effectively demonstrates that targeted education can bridge this knowledge–practice gap, empowering patients to actively participate in managing their condition and adhere to their treatment plans. The observed improvement in medication adherence, a crucial determinant of successful anticoagulation therapy, is particularly encouraging. Furthermore, the study breaks new ground by highlighting the potential of pharmacist-led education in mitigating bleeding risks associated with anticoagulation therapy. While previous studies predominantly focused on the impact of education on knowledge and adherence, this trial showcases a significant reduction in bleeding events, particularly minor bleeding episodes. This novel finding suggests that well-informed patients are better equipped to recognize and manage minor bleeding events, potentially averting unnecessary medical interventions and contributing to the overall reduction in bleeding risk observed in the study. This is a significant finding, as it challenges previous meta-analysis that failed to demonstrate a similar association2 and underscores the importance of providing comprehensive patient education that extends beyond medication management. Despite these promising results, several critical areas necessitate further consideration to maximize the impact of such interventions. Access to affordable oral anticoagulants (OACs), particularly the novel OACs (NOACs), remains a significant challenge. Novel oral anticoagulants offer several advantages over traditional vitamin K antagonists, including more convenient dosing regimens and fewer dietary restrictions.3 This trend is evident in the steady growth of direct OAC utilization over time and the concurrent decline in the usage of vitamin K antagonists.4 However, the uptake of OAC in low- and middle-income countries lags behind that observed in high-income countries.5,6 A cohort study undertaken in Hong Kong SAR, China, revealed that the utilization of anticoagulants among patients was suboptimal, with fewer than 40% receiving this treatment modality.7 This finding is corroborated by data from the China National Stroke Registry, which indicated that only 21% of patients presenting with acute ischaemic stroke and AF were prescribed anticoagulants upon discharge between 2012 and 2013.8 This rate stands in stark contrast to the significantly higher rate observed in the USA, where over 90% of comparable patients received anticoagulation therapy during the period from 2003 to 2009, as reported by the Get With the Guidelines–Stroke programme.5 This disparity highlights the urgent need to address financial barriers limiting NOAC accessibility, particularly for patients in resource-constrained settings. Not surprisingly, inadequate anticoagulation is linked to worse outcomes and higher overall mortality.6 The inclusion of NOACs in the World Health Organization’s Model List of Essential Medicines in 20199 represents a positive step towards improving accessibility. However, concerted governmental action is crucial to ensure these life-saving medications are universally accessible. Integrating NOACs into national drug formularies and securing adequate budget allocations are vital to overcome the financial hurdles currently hindering equitable access. Furthermore, the increasing availability of generic NOAC options presents an opportunity to further enhance affordability and bridge the treatment gap. Beyond cost considerations, addressing systemic barriers within healthcare systems is paramount to optimizing OAC utilization. The study by Xu et al. highlights the effectiveness of targeted interventions implemented within existing healthcare structures.1 Expanding such initiatives and tailoring them to specific patient populations based on factors like geographical location of diagnosis and the prescribing physician’s specialty10,11 can further enhance adherence and improve stroke prevention strategies. The study by Xu et al. provides compelling evidence for integrating pharmacist-led education programmes as a cornerstone of comprehensive AF management in China.1 By equipping patients with the knowledge and skills to actively participate in their care, these interventions hold the potential to significantly improve medication adherence, mitigate bleeding risks, and ultimately optimize patient outcomes. However, realizing the full potential of such interventions necessitates concurrent efforts to dismantle systemic barriers, particularly those hindering access to affordable NOACs. Ensuring equitable access to these life-saving medications is fundamental to bridging the treatment gap and achieving optimal anticoagulation care for all individuals living with atrial fibrillation. Franco Cheng (Conceptualization: Lead; Writing—original draft: Lead; Writing—review & editing: Lead) No new data were generated or analysed in support of this research.